All In Biotech

Drug Trial Radar · NCT03000530

A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder

A Phase 2, Two-Part (Open-Label Followed by Double-Blind) Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Adult Subjects With Moderate to Severe Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Nov 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

102

Actual

Start

Dec 7, 2016

Primary completion

Oct 4, 2017

Study completion Nov 8, 2017

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Dec 22, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-part (open-label followed by double-blind) study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in 102 participants diagnosed with moderate to severe Major Depressive Disorder.

Conditions

  • Major Depression

Interventions

  • SAGE-217Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) - Part ATime frame: Day 1 up to Day 21
  2. Percentage of Participants With TEAEs, Graded by Severity - Part ATime frame: Day 1 up to Day 21
  3. Change From Baseline in Basophils - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  4. Change From Baseline in Basophils to Leukocytes Ratio [Percentage (%)] - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  5. Change From Baseline in Eosinophils - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  6. Change From Baseline in Eosinophils to Leukocytes Ratio (%) - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  7. Change From Baseline in Hematocrit - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  8. Change From Baseline in Hemoglobin - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  9. Change From Baseline in Lymphocytes - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  10. Change From Baseline in Lymphocytes to Leukocytes Ratio (%) - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  11. Change From Baseline in Monocytes - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  12. Change From Baseline in Monocytes to Leukocytes Ratio (%) - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  13. Change From Baseline in Neutrophils - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  14. Change From Baseline in Neutrophils to Leukocytes Ratio (%) - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  15. Change From Baseline in Platelets - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  16. Change From Baseline in Erythrocytes - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  17. Change From Baseline in Reticulocytes - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  18. Change From Baseline in Leukocytes - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  19. Change From Baseline in Albumin - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  20. Change From Baseline in Alkaline Phosphatase - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  21. Change From Baseline in Alanine Aminotransferase - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  22. Change From Baseline in Aspartate Aminotransferase - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  23. Change From Baseline in Bilirubin - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  24. Change From Baseline in Chloride - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  25. Change From Baseline in Carbon Dioxide - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  26. Change From Baseline in Creatinine - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  27. Change From Baseline in Potassium - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  28. Change From Baseline in Protein - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  29. Change From Baseline in Sodium - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  30. Change From Baseline in Urea Nitrogen - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  31. Change From Baseline in Activated Partial Thromboplastin Time - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  32. Change From Baseline in Prothrombin International Normalized Ratio (%) - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  33. Change From Baseline in Prothrombin Time - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  34. Change From Baseline in pH - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  35. Change From Baseline in Specific Gravity - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
  36. Change From Baseline (CFB) in Supine Systolic Blood Pressure - Part ATime frame: Baseline, Day 1 (0.25, 0.5, 1, 2, 12 hours postdose), Days 2, 3, 4, 5, 6 and 7 (predose, 0.25, 0.5, 1, 2, 12 hours postdose), Days 8, 9, 10, 11, 12, 13 and 14 (predose, 1 hour postdose), Day 15/ET, follow-up Day 21, follow-up Day 28
  37. Change From Baseline (CFB) in Supine Diastolic Blood Pressure - Part ATime frame: Baseline, Day 1 (0.25, 0.5, 1, 2, 12 hours postdose), Days 2, 3, 4, 5, 6 and 7 (predose, 0.25, 0.5, 1, 2, 12 hours postdose), Days 8, 9, 10, 11, 12, 13 and 14 (predose, 1 hour postdose), Day 15/ET, follow-up Day 21, follow-up Day 28
  38. Change From Baseline (CFB) in Standing Systolic Blood Pressure - Part ATime frame: Baseline, Day 1 (0.25, 0.5, 1, 2, 12 hours postdose), Days 2, 3, 4, 5, 6 and 7 (predose, 0.25, 0.5, 1, 2, 12 hours postdose), Days 8, 9, 10, 11, 12, 13 and 14 (predose, 1 hour postdose), Day 15/ET, follow-up Day 21, follow-up Day 28
  39. Change From Baseline (CFB) in Standing Diastolic Blood Pressure - Part ATime frame: Baseline, Day 1 (0.25, 0.5, 1, 2, 12 hours postdose), Days 2, 3, 4, 5, 6 and 7 (predose, 0.25, 0.5, 1, 2, 12 hours postdose), Days 8, 9, 10, 11, 12, 13 and 14 (predose, 1 hour postdose), Day 15/ET, follow-up Day 21, follow-up Day 28
  40. Change From Baseline (CFB) in Heart Rate - Part ATime frame: Baseline, Day 1 (0.25, 0.5, 1, 2, 12 hours postdose), Days 2, 3, 4, 5, 6 and 7 (predose, 0.25, 0.5, 1, 2, 12 hours postdose), Days 8, 9, 10, 11, 12, 13 and 14 (predose, 1 hour postdose), Day 15/ET, follow-up Day 21, follow-up Day 28
  41. Change From Baseline (CFB) in Respiratory Rate - Part ATime frame: Baseline, Day 1 (0.25, 0.5, 1, 2, 12 hours postdose), Days 2, 3, 4, 5, 6 and 7 (predose, 0.25, 0.5, 1, 2, 12 hours postdose), Days 8, 9, 10, 11, 12, 13 and 14 (predose, 1 hour postdose), Day 15/ET, follow-up Day 21, follow-up Day 28
  42. Change From Baseline (CFB) in Oral Temperature - Part ATime frame: Baseline, Day 1 (0.25, 0.5, 1, 2, 12 hours postdose), Days 2, 3, 4, 5, 6 and 7 (predose, 0.25, 0.5, 1, 2, 12 hours postdose), Days 8, 9, 10, 11, 12, 13 and 14 (predose, 1 hour postdose), Day 15/ET, follow-up Day 21, follow-up Day 28
  43. Change From Baseline (CFB) in Oxygen Saturation - Part ATime frame: Baseline, Day 1 (0.25, 0.5, 1, 2, 12 hours postdose), Days 2, 3, 4, 5, 6 and 7 (predose, 0.25, 0.5, 1, 2, 12 hours postdose), Day 8 (predose, 1 hour postdose)
  44. Change From Baseline in QT Interval - Part ATime frame: Baseline, Days 1, 2, 7, 14 and follow-up Day 21
  45. Change From Baseline in QTcF Interval - Part ATime frame: Baseline, Days 1, 2, 7, 14 and follow-up Day 21
  46. Change From Baseline in ECG Mean Heart Rate - Part ATime frame: Baseline, Days 1, 2, 7, 14 and follow-up Day 21
  47. Change From Baseline in RR Interval - Part ATime frame: Baseline, Days 1, 2, 7, 14 and follow-up Day 21
  48. Change From Baseline in PR Interval - Part ATime frame: Baseline, Days 1, 2, 7, 14 and follow-up Day 21
  49. Change From Baseline in QRS Interval - Part ATime frame: Baseline, Days 1, 2, 7, 14 and follow-up Day 21
  50. Percentage of Participants With a Response of 'Yes' to Any Columbia Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation Item - Part ATime frame: Day 1 up to Day 28
  51. Change From Baseline in Stanford Sleepiness Scale (SSS) Score at Day 15 - Part ATime frame: Baseline, Day 15
  52. Change From Baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15 - Part BTime frame: Baseline, Day 15

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Sage Investigational Site

    Garden Grove, California

  • Sage Investigational Site

    Orlando, Florida

  • Sage Investigational Site

    Atlanta, Georgia

  • Sage Investigational Site

    Lake Charles, Louisiana

  • Sage Investigational Site

    Berlin, New Jersey

  • Sage Investigational Site

    Dayton, Ohio

  • Sage Investigational Site

    Austin, Texas

  • Sage Investigational Site

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.